Expectations for Artificial Intelligence (AI) in Psychiatry.

Artificial intelligence Machine learning Psychiatry Technology maturity

Journal

Current psychiatry reports
ISSN: 1535-1645
Titre abrégé: Curr Psychiatry Rep
Pays: United States
ID NLM: 100888960

Informations de publication

Date de publication:
11 2022
Historique:
accepted: 15 09 2022
pubmed: 11 10 2022
medline: 8 11 2022
entrez: 10 10 2022
Statut: ppublish

Résumé

Artificial intelligence (AI) is often presented as a transformative technology for clinical medicine even though the current technology maturity of AI is low. The purpose of this narrative review is to describe the complex reasons for the low technology maturity and set realistic expectations for the safe, routine use of AI in clinical medicine. For AI to be productive in clinical medicine, many diverse factors that contribute to the low maturity level need to be addressed. These include technical problems such as data quality, dataset shift, black-box opacity, validation and regulatory challenges, and human factors such as a lack of education in AI, workflow changes, automation bias, and deskilling. There will also be new and unanticipated safety risks with the introduction of AI. The solutions to these issues are complex and will take time to discover, develop, validate, and implement. However, addressing the many problems in a methodical manner will expedite the safe and beneficial use of AI to augment medical decision making in psychiatry.

Identifiants

pubmed: 36214931
doi: 10.1007/s11920-022-01378-5
pii: 10.1007/s11920-022-01378-5
pmc: PMC9549456
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

709-721

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Scott Monteith (S)

Michigan State University College of Human Medicine, Traverse City Campus, Traverse City, MI, 49684, USA. monteit2@msu.edu.

Tasha Glenn (T)

ChronoRecord Association, Fullerton, CA, USA.

John Geddes (J)

Department of Psychiatry, University of Oxford, Warneford Hospital, Oxford, UK.

Peter C Whybrow (PC)

Department of Psychiatry and Biobehavioral Sciences, Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

Eric Achtyes (E)

Michigan State University College of Human Medicine, Grand Rapids, MI, 49684, USA.
Network180, Grand Rapids, MI, USA.

Michael Bauer (M)

Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus Medical Faculty, Technische Universität Dresden, Dresden, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH